Litigation provision
Medtronic Litigation provision remained flat by 0.0% to $28.25M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 64.4%, from $79.25M to $28.25M. Over 2 years (FY 2024 to FY 2026), Litigation provision shows a downward trend with a -12.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests rising legal risks, potential product liability issues, or unfavorable outcomes in ongoing litigation, which may negatively impact future cash flows and reputation. A decrease indicates a reduction in legal exposure or the resolution of significant outstanding disputes.
Detailed definition
This metric represents the net charges recognized in the income statement related to legal proceedings, settlements, or...
Peer comparison
Peers in the medical device and pharmaceutical sectors often report similar charges due to the high-stakes nature of patent litigation and product liability claims; investors typically compare these to total revenue to assess the relative burden of legal risk.
operating_expenses_loss_contingency_loss_in_periodHistorical Data
| FY'24 | FY'25 | FY'26 | |
|---|---|---|---|
| Value | $149M | $317M | $113M |
| YoY Change | — | +112.8% | -64.4% |
Litigation provision at Other Companies
Frequently Asked Questions
- What is Medtronic's litigation provision?
- Medtronic (MDT) reported litigation provision of $28.25M in Q1 2026.
- How has Medtronic's litigation provision changed year-over-year?
- Medtronic's litigation provision decreased by 64.4% year-over-year, from $79.25M to $28.25M.
- What is the long-term trend for Medtronic's litigation provision?
- Over 2 years (2024 to 2026), Medtronic's litigation provision has grown at a -12.9% compound annual growth rate (CAGR), from $149M to $113M.
- What does litigation provision mean?
- The net financial cost recognized during the period due to legal settlements, litigation, or related loss contingencies.